MA54875A - Compositions oligonucléotidiques et procédés associés - Google Patents

Compositions oligonucléotidiques et procédés associés

Info

Publication number
MA54875A
MA54875A MA054875A MA54875A MA54875A MA 54875 A MA54875 A MA 54875A MA 054875 A MA054875 A MA 054875A MA 54875 A MA54875 A MA 54875A MA 54875 A MA54875 A MA 54875A
Authority
MA
Morocco
Prior art keywords
related methods
oligonucleotide compositions
oligonucleotide
compositions
methods
Prior art date
Application number
MA054875A
Other languages
English (en)
Inventor
Kidist M Aklilu
Shaunna Syu-Mei Berkovitch
Duncan Parley Brown
Jeffrey Matthew Brown
Maria David Frank-Kamenetsky
Naoki Iwamoto
Chandra Vargeese
Original Assignee
Wave Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wave Life Sciences Ltd filed Critical Wave Life Sciences Ltd
Publication of MA54875A publication Critical patent/MA54875A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/34—Allele or polymorphism specific uses
MA054875A 2019-02-01 2020-01-30 Compositions oligonucléotidiques et procédés associés MA54875A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962800409P 2019-02-01 2019-02-01
US201962911335P 2019-10-06 2019-10-06

Publications (1)

Publication Number Publication Date
MA54875A true MA54875A (fr) 2021-12-08

Family

ID=71840465

Family Applications (1)

Application Number Title Priority Date Filing Date
MA054875A MA54875A (fr) 2019-02-01 2020-01-30 Compositions oligonucléotidiques et procédés associés

Country Status (14)

Country Link
US (1) US20220098585A1 (fr)
EP (1) EP3917497A4 (fr)
JP (1) JP2022519019A (fr)
KR (1) KR20210121199A (fr)
CN (1) CN113423385A (fr)
AU (1) AU2020216186A1 (fr)
BR (1) BR112021014940A2 (fr)
CA (1) CA3126845A1 (fr)
IL (1) IL284882A (fr)
MA (1) MA54875A (fr)
MX (1) MX2021009178A (fr)
SG (1) SG11202107318YA (fr)
TW (1) TW202045189A (fr)
WO (1) WO2020160336A1 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112015000784A8 (pt) 2012-07-13 2018-04-03 Wave Life Sciences Japan Grupo auxiliar assimétrico
EP2872147B1 (fr) 2012-07-13 2022-12-21 Wave Life Sciences Ltd. Procede de fabrication d'oligonucleotides chiraux
MA43072A (fr) 2015-07-22 2018-05-30 Wave Life Sciences Ltd Compositions d'oligonucléotides et procédés associés
CA3015823A1 (fr) 2016-03-13 2017-09-21 Wave Life Sciences Ltd. Compositions et procedes de synthese de phosphoramidite et d'oligonucleotides
MA45188A (fr) 2016-06-03 2019-04-10 Wave Life Sciences Ltd Oligonucléotides, compositions et méthodes associées
US11873316B2 (en) 2016-11-23 2024-01-16 Wave Life Sciences Ltd. Compositions and methods for phosphoramidite and oligonucleotide synthesis
US11597927B2 (en) 2017-06-02 2023-03-07 Wave Life Sciences Ltd. Oligonucleotide compositions and methods of use thereof
US11603532B2 (en) 2017-06-02 2023-03-14 Wave Life Sciences Ltd. Oligonucleotide compositions and methods of use thereof
WO2018237194A1 (fr) 2017-06-21 2018-12-27 Wave Life Sciences Ltd. Composés, compositions et procédés de synthèse
CN110996968A (zh) 2017-08-08 2020-04-10 波涛生命科学有限公司 寡核苷酸组合物及其方法
SG11202000276YA (en) 2017-09-18 2020-04-29 Wave Life Sciences Ltd Technologies for oligonucleotide preparation
US11596646B2 (en) 2017-10-12 2023-03-07 Wave Life Sciences Ltd. Oligonucleotide compositions and methods thereof
US11332733B2 (en) 2018-02-12 2022-05-17 lonis Pharmaceuticals, Inc. Modified compounds and uses thereof
AU2020395113A1 (en) 2019-12-02 2022-06-09 Shape Therapeutics Inc. Therapeutic editing
TW202334418A (zh) * 2021-10-29 2023-09-01 美商艾拉倫製藥股份有限公司 杭丁頓（ＨＴＴ）ｉＲＮＡ劑組成物及其使用方法
WO2023152371A1 (fr) 2022-02-14 2023-08-17 Proqr Therapeutics Ii B.V. Oligonucléotides guides pour l'édition d'acides nucléiques dans le traitement de l'hypercholestérolémie
WO2024013361A1 (fr) 2022-07-15 2024-01-18 Proqr Therapeutics Ii B.V. Oligonucléotides pour édition d'arn médiée par adar et leur utilisation
WO2024013360A1 (fr) 2022-07-15 2024-01-18 Proqr Therapeutics Ii B.V. Oligonucléotides chimiquement modifiés pour édition d'arn médiée par adar
WO2024035946A1 (fr) * 2022-08-11 2024-02-15 Wave Life Sciences Ltd. Compositions oligonucléotidiques et procédés associés

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0729474A4 (fr) * 1993-11-16 1998-10-21 Genta Inc Oligomeres synthetiques ayant des liaisons internucleosidyle phosphonate chiralement pures melangees avec des liaisons internucleosidyle non phosphonate
US8987222B2 (en) * 2009-04-08 2015-03-24 University Of Massachusetts Single nucleotide polymorphism (SNP) targeting therapies for the treatment of huntington'S disease
EP2534262B1 (fr) * 2010-02-08 2016-12-14 Ionis Pharmaceuticals, Inc. Réduction sélective de variants alléliques
US10202599B2 (en) * 2011-08-11 2019-02-12 Ionis Pharmaceuticals, Inc. Selective antisense compounds and uses thereof
WO2014059356A2 (fr) * 2012-10-12 2014-04-17 Isis Pharmaceuticals, Inc. Composés anti-sens sélectifs et leurs utilisations
MA43072A (fr) * 2015-07-22 2018-05-30 Wave Life Sciences Ltd Compositions d'oligonucléotides et procédés associés
MA45270A (fr) * 2016-05-04 2017-11-09 Wave Life Sciences Ltd Compositions d'oligonucléotides et procédés associés
CN110996968A (zh) * 2017-08-08 2020-04-10 波涛生命科学有限公司 寡核苷酸组合物及其方法

Also Published As

Publication number Publication date
CA3126845A1 (fr) 2020-08-06
AU2020216186A1 (en) 2021-07-29
JP2022519019A (ja) 2022-03-18
KR20210121199A (ko) 2021-10-07
CN113423385A (zh) 2021-09-21
US20220098585A1 (en) 2022-03-31
WO2020160336A1 (fr) 2020-08-06
BR112021014940A2 (pt) 2021-09-28
SG11202107318YA (en) 2021-08-30
IL284882A (en) 2021-08-31
EP3917497A1 (fr) 2021-12-08
TW202045189A (zh) 2020-12-16
MX2021009178A (es) 2021-09-08
EP3917497A4 (fr) 2023-06-07

Similar Documents

Publication Publication Date Title
MA54875A (fr) Compositions oligonucléotidiques et procédés associés
IL288284A (en) Circular Rana preparations and methods
SG11202105626TA (en) Oligonucleotide compositions and methods thereof
MA46427A (fr) Compositions d'oligonucléotides et procédés associés
MA43380A (fr) Récepteurs chimériques modifiés et compositions et procédés associés
IL277889A (en) Preparations of oligonucleotides and methods of using them
MA49858A (fr) Composés, compositions et procédés
SG11202001783YA (en) Oligonucleotide compositions and methods thereof
EP3664816A4 (fr) Compositions oligonucléotidiques et procédés associés
MA50063A (fr) Composés, compositions et procédés
DK3478811T3 (da) Rengøringssammensætninger og anvendelser deraf
MA42269A (fr) Compositions et procédés d'inhibition de l'activité de l'arginase
MA45270A (fr) Compositions d'oligonucléotides et procédés associés
MA45779A (fr) Polypeptides immunomdulateurs et compositions et procédés associés
MA54953A (fr) Composés, compositions et procédés
MA41558A (fr) Compositions d'allergènes mélangés et leurs procédés d'utilisation
MA50175A (fr) Formulation de valbenazine à dosage élevé et compositions, procédés et kits associés
MA54959A (fr) Composés, compositions et procédés
MA47613A (fr) Compositions et procédés de traitement du cancer
MA48797A (fr) Variants de l'endonucléase cblb , compositions et procédés d'utilisation
DK3702023T3 (da) Skråtstillet blandeapparat
IL279255A (en) Compositions and methods for evaluating genomic alterations
MA55087A (fr) Compositions et procédés de traitement de laminopathies
MA46586A (fr) Compositions de terlipressine et leurs procédés d'utilisation
MA54143A (fr) Compositions et méthodes